Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;32(1):76-80.
doi: 10.1111/ajad.13345. Epub 2022 Oct 12.

Polysubstance use profiles among US adults using Kratom (Mitragyna speciosa): A latent class analysis using The National Survey on Drug Use and Health (NSDUH)

Affiliations

Polysubstance use profiles among US adults using Kratom (Mitragyna speciosa): A latent class analysis using The National Survey on Drug Use and Health (NSDUH)

Alyssa M Falise et al. Am J Addict. 2023 Jan.

Abstract

Background and objectives: Kratom (Mitragyna speciosa) use is associated with polysubstance use (PSU) and use disorders. However, additional research on PSU heterogeneity in populations using this novel psychoactive substance is necessary. The authors investigated patterns of past 12-month PSU among US adults reporting past 12-month use of kratom and at least one additional substance.

Methods: Latent class models were fit using 2019 National Survey on Drug Use and Health (NSDUH) data which was collected from 412 US adults reporting past 12-month use of kratom and at least one of 11 additional substances.

Results: Three distinct profiles were identified: "marijuana/alcohol/tobacco" (63.3%), "marijuana/alcohol/tobacco + psychedelics" (19.3%), and "marijuana/alcohol/tobacco + psychedelics/heroin/prescriptions" (17.4%).

Conclusions and scientific significance: This is the first epidemiological study in which a latent class analysis was used to identify unique PSU profiles among US adults using kratom and other substances. Understanding the profiles of people using kratom in relation to the use of other drugs might help guide screening interventions, treatment needs, and policy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.

Figures

Figure 1.
Figure 1.. Predicted probabilities of past 12-month polysubstance use by latent profile (n = 412)
a MAT PSU = marijuana/alcohol/tobacco polysubstance use profile; MAT+P PSU = marijuana/alcohol/tobacco + psychedelics polysubstance use profile; MAT+PHPR PSU = marijuana/alcohol/tobacco + psychedelics/heroin/non-medical use of prescription drugs polysubstance use profile * indicates significance (p < 0.05)

References

    1. Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence. 2020;208:107849. doi:10.1016/j.drugalcdep.2020.107849 - DOI - PMC - PubMed
    1. Striley CW, Hoeflich CC, Viegas AT, et al. Health Effects Associated With Kratom (Mitragyna speciosa) and Polysubstance Use: A Narrative Review. Subst Abuse. 2022;16:11782218221095872. doi:10.1177/11782218221095873 - DOI - PMC - PubMed
    1. Henningfield JE, Grundmann O, Garcia-Romeu A, Swogger MT. We Need Better Estimates of Kratom Use Prevalence. Am J Prev Med. 2022;62(1):132–133. doi:10.1016/j.amepre.2021.07.022 - DOI - PubMed
    1. Post S, Spiller HA, Chounthirath T, Smith GA. Kratom exposures reported to United States poison control centers: 2011–2017. Clinical Toxicology. 2019;57(10):847–854. doi:10.1080/15563650.2019.1569236 - DOI - PubMed
    1. Corkery JM, Streete P, Claridge H, et al. Characteristics of deaths associated with kratom use. J Psychopharmacol. 2019;33(9):1102–1123. doi:10.1177/0269881119862530 - DOI - PubMed

Publication types